Navigation Links
HydroCision Announces New Investment to Accelerate Growth of Novel Fluidjet Technology for Minimally Invasive Spine Surgery
Date:9/15/2010

NORTH BILLERICA, Mass., Sept. 15 /PRNewswire/ -- HydroCision Inc. (www.hydrocision.com), a privately held medical device company, announced today the purchase of the majority of the Company by new investors, led by venture capital firms Volcano Capital, Bioventures, and Omega Funds. HydroCision is the developer, manufacturer, and marketer of SpineJet®, whose innovative Fluidjet surgical technology allows discectomy and interbody fusion procedures to be performed faster, less invasively, and with a higher degree of precision than traditional surgical modalities.

The parties also announced the appointment of Howard Donnelly to the position of President and CEO of HydroCision. Donnelly has more than 20 years of executive-level experience in the medical device industry.  In addition to serving on several medical device company boards, he was the past President of Level 1, a medical device subsidiary of Smiths Group.

HydroCision will focus on several core strategies designed to strengthen its worldwide position in the spine market. "The global market for minimally invasive spine procedures is growing rapidly," noted Donnelly.  "This new investment and strategic direction will allow HydroCision to extend its technology leadership with a very strong product suite that will benefit both clinicians and patients."

HydroCision plans to invest in U.S.-based research projects to further validate the clinical and economic value of HydroCision products for the medical community and the insurance industry. "We believe a stronger medico-economic justification for the use of our products will afford us the platform we need to scale adoption in the U.S. and OUS markets," said Donnelly.

HydroCision's SpineJet system has been widely accepted by spine surgeons as breakthrough technology for decompression and fusion procedures. Until SpineJet, spine surgeons were primarily relying on manual instrumentation to perform delicate procedures through increasingly smaller incisions. "The HydroSurgery® approach made possible by HydroCision's technology provides spine surgeons with an efficient new tool," said Mitchell Hardenbrook, M.D., an orthopedic surgeon at the Boston Spine Group in Boston, Mass. "SpineJet has empowered us to perform truly minimally invasive fusion procedures that lead to improved clinical outcomes and faster patient recovery."

About HydroCision HydroCision (http://www.hydrocision.com) is the leading developer, manufacturer, and marketer of fluidjet-based surgical tools for minimally invasive spine surgery. HydroCision's proprietary Fluidjet technology is the basis of a new surgical modality, "HydroSurgery®," which has the power density of laser and radiofrequency technologies, but does not cause thermal tissue damage. HydroCision's signature product is the SpineJet HydroSurgery System. Since its introduction in 2005, the SpineJet system has been used in more than 45,000 spinal, arthroscopic and wound debridement procedures.Contact: Paul Kowalski978-474-9300pkowalski@hydrocision.com
'/>"/>

SOURCE HydroCision Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
2. China Cord Blood Corporation Announces Mandate for Share Repurchase Program
3. China Cord Blood Corporation Announces Framework Agreement Regarding Fourth License - Zhejiang Province
4. Compandia Announces Name Change and New Diagnostic Concept
5. 3SBio Announces Partial Conversion of Isotechnika Debenture
6. ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000
7. Neurocrine Announces Top-Line Results of Corticotropin Releasing Factor Antagonist GSK561679 for Treatment of Major Depressive Disorder
8. Wintherix Announces Potent Small Molecule Wnt Activators for Bone Healing.
9. Southern Research Announces Completion of $20 Million Bond Transaction
10. Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
11. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
(Date:9/18/2017)... Pa. and KALAMAZOO, Mich. , Sept. 18, ... , and OptiMed Specialty Pharmacy of ... to offer a strategic hub service that expedites and ... sought-after personal spirometer, Spiro PD 2.0, and wellness management ... spirometer is a medical device used to measure lung ...
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent review ... as the number one company for hearing aids, ranking it higher ... other brands. ... Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, state-of-the-art, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will ... the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey ... Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division ...
Breaking Medicine News(10 mins):